

Prostate cancer genetic testing



INVITAE PROSTATE CANCER PANEL

Invitae offers comprehensive genetic testing for patients at risk for hereditary prostate cancer. More than 180,000 cases of prostate cancer are diagnosed each year; 5–10% of those are expected to be hereditary.^{1,2}

Pathogenic variants in *BRCA1* and *BRCA2* are only part of the story. Invitae's comprehensive prostate cancer panel targets up to 14 genes that evidence associates with a hereditary predisposition to prostate cancer:

ATM, BRCA1, BRCA2, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51D, TP53


Results from the Invitae Prostate Cancer Panel can help guide medical management for both your patient and their family, including treatments such as PARP inhibitors, platinum agents, and immunotherapy.

CONSIDERATIONS FOR TESTING

This panel may be appropriate if your patient or their family members have:


- **Metastatic prostate cancer**
- **Rare cancers** including male breast cancer or ovarian cancer
- Cancer diagnosed at a **young age** (<50 years)
- **Multiple cancers** (e.g., 2+ primary cancers in the same person or 3+ diagnoses on the same side of the family)
- A **known pathogenic genetic variant** in the family

INVITAE PROSTATE CANCER PANEL VARIANT DISTRIBUTION³



**EPCAM, MLH1, MSH2, MSH6, and PMS2*

LIFETIME RISKS



BENEFITS OF TESTING WITH INVITAE

Invitae is a genetic information company whose mission is to bring genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. We offer:

- High-quality results backed by peer-reviewed studies
- STAT panels (results in 7 days on average) for urgent treatment decisions
- Ability to follow up with additional oncology genes at no additional charge
- In-network status for more than 190 million patients in the United States—and growing

¹Cancer Genome Atlas Research Network. *Cell*, 2015.
²Pritchard, CC. *et al. NEJM*, 2016.
³Piper LW Nicolosi, *et al.* Presented at ASCO Annual Meeting; June 2017; Chicago, Illinois.